FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241627887> ?p ?o ?g. }

• W4241627887 abstract "In preterm newborns, the ductus arteriosus frequently fails to close and the infants require medical or surgical closure of the patent ductus arteriosus (PDA). A PDA can be treated surgically; or medically with one of two prostaglandin inhibitors, indomethacin or ibuprofen. Case reports suggest that paracetamol may be an alternative for the closure of a PDA. An association between prenatal or postnatal exposure to paracetamol and later development of autism or autism spectrum disorder has been reported.To determine the effectiveness and safety of intravenous or oral paracetamol compared with placebo or no intervention, intravenous indomethacin, intravenous or oral ibuprofen, or with other cyclo-oxygenase inhibitors for treatment of an echocardiographically diagnosed PDA in preterm or low birth weight infants.We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2017, Issue 10), MEDLINE via PubMed (1966 to 6 November 2017), Embase (1980 to 6 November 2017), and CINAHL (1982 to 6 November 2017). We searched clinical trial databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials (RCT) and quasi-randomised trials.We included RCTs in which paracetamol was compared to no intervention, placebo or other agents used for closure of PDA irrespective of dose, duration and mode of administration in preterm (≤ 34 weeks' postmenstrual age) infants. We both reviewed the search results and made a final selection of potentially eligible articles by discussion. We included studies of both prophylactic and therapeutic use of paracetamol.We performed data collection and analyses in accordance with the methods of the Cochrane Neonatal Review Group. We used the GRADE approach to assess the quality of evidence for the following outcomes when data were available: failure of ductal closure after the first course of treatment; neurodevelopmental impairment; all-cause mortality during initial hospital stay (death); gastrointestinal bleed or stools positive for occult blood; and serum levels of creatinine after treatment (µmol/L).We included eight studies that reported on 916 infants. One of these studies compared paracetamol to both ibuprofen and indomethacin. Five studies compared treatment of PDA with paracetamol versus ibuprofen and enrolled 559 infants. There was no significant difference between paracetamol and ibuprofen for failure of ductal closure after the first course of drug administration (typical risk ratio (RR) 0.95, 95% confidence interval (CI) 0.75 to 1.21; typical risk difference (RD) -0.02, 95% CI -0.09 to 0.09); I² = 0% for RR and RD; moderate quality of evidence. Four studies (n = 537) reported on gastrointestinal bleed which was lower in the paracetamol group versus the ibuprofen group (typical RR 0.28, 95% CI 0.12 to 0.69; typical RD -0.06, 95% CI -0.09 to -0.02); I² = 0% for RR and RD; number needed to treat for an additional beneficial outcome (NNTB) 17 (95% CI 11 to 50); moderate quality of evidence. The serum levels of creatinine were lower in the paracetamol group compared with the ibuprofen group in four studies (moderate quality of evidence), as were serum bilirubin levels following treatment in two studies (n = 290). Platelet counts and daily urine output were higher in the paracetamol group compared with the ibuprofen group. One study reported on long-term follow-up to 18 to 24 months of age following treatment with paracetamol versus ibuprofen. There were no significant differences in the neurological outcomes at 18 to 24 months (n = 61); (low quality of evidence). Two studies compared prophylactic administration of paracetamol for a PDA with placebo or no intervention in 80 infants. Paracetamol resulted in a lower rate of failure of ductal closure after 4 to 5 days of treatment compared to placebo or no intervention which was of borderline significance for typical RR 0.49 (95% CI 0.24 to 1.00; P = 0.05); but significant for typical RD -0.21 (95% CI -0.41 to -0.02); I² = 0 % for RR and RD; NNTB 5 (95% CI 2 to 50); (low quality of evidence). Two studies (n = 277) compared paracetamol with indomethacin. There was no significant difference in the failure to close a PDA (typical RR 0.96, 95% CI 0.55 to 1.65; I² = 11%; typical RD -0.01, 95% CI -0.09 to 0.08; I² = 17%) (low quality of evidence). Serum creatinine levels were significantly lower in the paracetamol group compared with the indomethacin group and platelet counts and daily urine output were significantly higher in the paracetamol group.Moderate-quality evidence according to GRADE suggests that paracetamol is as effective as ibuprofen; low-quality evidence suggests paracetamol to be more effective than placebo or no intervention; and low-quality evidence suggests paracetamol as effective as indomethacin in closing a PDA. There was no difference in neurodevelopmental outcome in children exposed to paracetamol compared to ibuprofen; however the quality of evidence is low and comes from only one study. In view of concerns raised regarding neurodevelopmental outcomes following prenatal and postnatal exposure to paracetamol, long-term follow-up to at least 18 to 24 months' postnatal age must be incorporated in any studies of paracetamol in the newborn population. At least 19 ongoing trials have been registered. Such trials are required before any recommendations for the possible routine use of paracetamol in the newborn population can be made." @default.
• W4241627887 created "2022-05-12" @default.
• W4241627887 creator A5035738307 @default.
• W4241627887 creator A5046655310 @default.
• W4241627887 date "2020-01-27" @default.
• W4241627887 modified "2023-10-10" @default.
• W4241627887 title "Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants" @default.
• W4241627887 cites W1578545245 @default.
• W4241627887 cites W163151552 @default.
• W4241627887 cites W1634569198 @default.
• W4241627887 cites W1723431032 @default.
• W4241627887 cites W1957857943 @default.
• W4241627887 cites W1961926657 @default.
• W4241627887 cites W1964296185 @default.
• W4241627887 cites W1974011879 @default.
• W4241627887 cites W1974980648 @default.
• W4241627887 cites W1977958430 @default.
• W4241627887 cites W1981001200 @default.
• W4241627887 cites W1982567104 @default.
• W4241627887 cites W1983754062 @default.
• W4241627887 cites W1984923791 @default.
• W4241627887 cites W2011258930 @default.
• W4241627887 cites W2019549525 @default.
• W4241627887 cites W2020861220 @default.
• W4241627887 cites W2022878856 @default.
• W4241627887 cites W2024824040 @default.
• W4241627887 cites W2043529543 @default.
• W4241627887 cites W2046224781 @default.
• W4241627887 cites W2056054691 @default.
• W4241627887 cites W2062309170 @default.
• W4241627887 cites W2067034215 @default.
• W4241627887 cites W2072434585 @default.
• W4241627887 cites W2092815901 @default.
• W4241627887 cites W2096169136 @default.
• W4241627887 cites W2108978001 @default.
• W4241627887 cites W2111575740 @default.
• W4241627887 cites W2114604788 @default.
• W4241627887 cites W2117425969 @default.
• W4241627887 cites W2124588783 @default.
• W4241627887 cites W2125435699 @default.
• W4241627887 cites W2126305604 @default.
• W4241627887 cites W2131860883 @default.
• W4241627887 cites W2138535033 @default.
• W4241627887 cites W2147433746 @default.
• W4241627887 cites W2149101474 @default.
• W4241627887 cites W2170270071 @default.
• W4241627887 cites W2325579627 @default.
• W4241627887 cites W2400345141 @default.
• W4241627887 cites W2405315705 @default.
• W4241627887 cites W2411498720 @default.
• W4241627887 cites W2465836960 @default.
• W4241627887 cites W2491414039 @default.
• W4241627887 cites W2519326222 @default.
• W4241627887 cites W2565382690 @default.
• W4241627887 cites W2605723324 @default.
• W4241627887 cites W2738649782 @default.
• W4241627887 cites W2744986593 @default.
• W4241627887 cites W2755237105 @default.
• W4241627887 cites W2767021994 @default.
• W4241627887 cites W2782606979 @default.
• W4241627887 cites W2791940903 @default.
• W4241627887 cites W2793360052 @default.
• W4241627887 cites W3148465273 @default.
• W4241627887 cites W4247665917 @default.
• W4241627887 cites W4248251600 @default.
• W4241627887 cites W2408841882 @default.
• W4241627887 cites W4290127353 @default.
• W4241627887 doi "https://doi.org/10.1002/14651858.cd010061.pub4" @default.
• W4241627887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31985831" @default.
• W4241627887 hasPublicationYear "2020" @default.
• W4241627887 type Work @default.
• W4241627887 citedByCount "55" @default.
• W4241627887 countsByYear W42416278872020 @default.
• W4241627887 countsByYear W42416278872021 @default.
• W4241627887 countsByYear W42416278872022 @default.
• W4241627887 countsByYear W42416278872023 @default.
• W4241627887 crossrefType "journal-article" @default.
• W4241627887 hasAuthorship W4241627887A5035738307 @default.
• W4241627887 hasAuthorship W4241627887A5046655310 @default.
• W4241627887 hasBestOaLocation W42416278872 @default.
• W4241627887 hasConcept C126322002 @default.
• W4241627887 hasConcept C142724271 @default.
• W4241627887 hasConcept C168563851 @default.
• W4241627887 hasConcept C187212893 @default.
• W4241627887 hasConcept C204787440 @default.
• W4241627887 hasConcept C27081682 @default.
• W4241627887 hasConcept C2776478404 @default.
• W4241627887 hasConcept C2778376644 @default.
• W4241627887 hasConcept C2778722691 @default.
• W4241627887 hasConcept C2779083892 @default.
• W4241627887 hasConcept C2779234561 @default.
• W4241627887 hasConcept C2779944601 @default.
• W4241627887 hasConcept C2781236024 @default.
• W4241627887 hasConcept C42219234 @default.
• W4241627887 hasConcept C535046627 @default.
• W4241627887 hasConcept C54355233 @default.
• W4241627887 hasConcept C66322754 @default.
• W4241627887 hasConcept C71924100 @default.
• W4241627887 hasConcept C86803240 @default.
• W4241627887 hasConcept C98274493 @default.

• next